The founders of Diabetology have been working in the field for over thirty years, and have accumulated a wealth of experience which has led to the development of its state-of-the-art technologies.
The disease is one which affects a large number of people in many different ways, and we believe our proprietary technologies, enabling ingestion of insulin and other protein drugs via the oral route, can bring back normality to the lives of diabetes and obesity sufferers. Oral insulin and oral GLP1’s are not only more convenient for the patient, but may avoid certain complications of the disease, improving the patients’ general health and well-being.
This is more important now than ever, in light of the increasing incidence of diabetes and obesity all over the world.
Our leadership team brings together deep industry expertise, strategic vision, and a commitment to innovation in Diabetology.
30 years of research & development in diabetes and obesity, and taking various products to market.
Cofounder funding support over 25 years. Contributed to over 1 million lives saved and $100m+ in third party Revenues
We have worked with over 30 leading medical institutions and research partners worldwide.
2024 – Australia
2011 – Europe
2010 – Europe
“At Diabetology, our mission is to translate scientific innovation into practical, safe, physiological, patient-centered solutions that improve metabolic health outcomes. We are committed to advancing research, precision formulation, and long-term therapeutic impact.”
Glen Travers
Co Founder
Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.
Copyright © 2026 Diabetology Ltd. All rights reserved.
Co Founder
25 years experience building healthcare businesses, successfully taken several therapeutics and diagnostics to market, some partnered with major multinational pharmaceutical companies.
Co-founded and built biopharmaceutical company Cortecs Ltd to peak $1bn value, $0.5bn on departure, company shared royalties with Nobel Laureates for Helicobacter Diagnostics.
Chief Scientific Officer and Co-Founder
Chief Financial Officer Director Diabetology International Pty Ltd
Advisor
Chief Laboratory Manager & Project Oversight
(DPsych, MPhil Cantab, BAHons, DipN) Eating Disorders, Director Axcess Ltd
Consulting Medical Officer
Analyst
A University of Cambridge–trained scientist with an MA in Natural Sciences, shaped by Cambridge’s rigorous emphasis on critical thinking, experimental design, and evidence‑driven research.
Building on experience as a Business Analyst in a tech start-up, she combines scientific biological knowledge with commercial awareness to help organisations.
Business Development, Manufacture, Corporate Leadership Advisor
Coming Soon
Leading Clinical Advisor
As founding principal in 1997, Dr. Sampalis played a central role in establishing the company’s strategic vision, building its global footprint, and shaping its operational model.
While no longer involved in daily operations, Dr. Sampalis continues to contribute to the organization in an advisory capacity, working closely with the Board of Directors and supporting the organization’s long-term strategic development.
Dr. Sampalis is a tenured professor of Surgery and Epidemiology & Biostatistics of McGill University, the University of Montreal and Laval, University. Throughout his career he has received numerous scholarships from provincial and federal funding agencies including the Medical Research Council of Canada, the National Health Development Program and the Fonds de la recherche en santé du Quebec, and is recognized as a leading clinical epidemiologist and trauma researcher.
Dean of Physiology Oxford University
Advisor
Co-head, Diabetes and Obesity Research MBBS DCH FRACP MD
Areas of research expertise: Diabetes Mellitus, youth, hypoglycaemia, metabolism
As well as Head of Diabetes and Obesity Research at The Kids, Kids Research Institute, Professor Jones is a Clinical Professor at The University of Western Australia and Co-Director of Medicine at Perth Children’s Hospital.
Professor Jones received his paediatric training in Australia and the UK and his post doctoral training at Yale University, USA.
Professor Jones is internationally recognised for clinical investigation in childhood diabetes, in particular in hypoglycaemia and diabetes treatments and technologies; and leads a research team based at The Kids Research Institute Australia and Perth Children’s Hospital.
Advisor Consultant
Professor Merlin Thomas is a clinician-scientist and program leader in the Department of Diabetes at Monash University, Australia. He is also a Fellow of the Australian Academy of Medical Science and Founder of RAGE Biotech. His research program is focused on understanding the mechanisms of diabetic complications and developing new opportunities for their prevention and treatment.
